title: Stability of three commonly compounded extemporaneous enrofloxacin suspensions for oral administration to exotic animals.
abstract: OBJECTIVE
  To evaluate the stability of 3 extemporaneous oral suspensions of enrofloxacin mixed with readily available flavoring vehicles when stored at room temperature (approx 22°C).
  
  
  METHODS
  Evaluation study.
  
  
  METHODS
  3 commonly compounded oral suspensions of enrofloxacin.
  
  
  METHODS
  On day 0, commercially available enrofloxacin tablets were compounded with a mixture of distilled water and corn syrup (formulation A) or cherry syrup (formulation B) flavoring vehicles to create suspensions with a nominal enrofloxacin concentration of 22.95 mg/mL, and 2.27% enrofloxacin injectable solution was compounded with a liquid sweetener (formulation C) to create a suspension with a nominal enrofloxacin concentration of 11.35 mg/mL. Preparations were stored in amber-colored vials at room temperature for 56 days. For each preparation, the enrofloxacin concentration was evaluated with high-performance liquid chromatography at prespecified intervals during the study. The pH, odor, and consistency for all suspensions were recorded at the start and completion of the study.
  
  
  RESULTS
  Relative to the nominal enrofloxacin concentration, the enrofloxacin concentration strength ranged from 95.80% to 100.69% for formulation A, 108.44% to 111.06% for formulation B, and 100.99% to 103.28% for formulation C. A mild pH increase was detected in all 3 suspensions during the study.
  
  
  CONCLUSIONS
  Results indicated that, when stored in amber-colored vials at room temperature for 56 days, the enrofloxacin concentration strength in all 3 formulations was retained within acceptance criteria of 90% to 110%. Subjectively, cherry syrup flavoring was better at masking the smell and taste of enrofloxacin than were the other mixing vehicles.
authors.affiliation: Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California-Davis, Davis, CA 95616, USA.
authors.forename: Olivia A
authors.initials: OA
authors.lastname: Petritz
authors.forename: David Sanchez-Migallon
authors.initials: DS
authors.lastname: Guzman
authors.forename: Valerie J
authors.initials: VJ
authors.lastname: Wiebe
authors.forename: Mark G
authors.initials: MG
authors.lastname: Papich
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000737:chemistry*; D004339:Drug Compounding; D004355:Drug Stability; D000077422:Enrofloxacin; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000737:chemistry*; D057805:Pets; D013535:Suspensions / Q000737:chemistry
chemical_list: D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D013535:Suspensions; D000077422:Enrofloxacin